Accumulation and propagation of hyperphosphorylated Tau (p-Tau) is a common neuropathological hallmark associated with neurodegeneration of Alzheimer's disease (AD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), and related tauopathies. Extracellular vesicles, specifically exosomes, have recently been demonstrated to participate in mediating Tau propagation in brain. Exosomes produced by human induced pluripotent stem cell (iPSC)-derived neurons expressing mutant Tau (mTau), containing the P301L and V337M Tau mutations of FTDP-17, possess the ability to propagate p-Tau pathology after injection into mouse brain. To gain an understanding of the mTau exosome cargo involved in Tau pathogenesis, these pathogenic exosomes were analyzed by proteomics and bioinformatics. The data showed that mTau expression dysregulates the exosome proteome to result in 1) proteins uniquely present only in mTau, and not control exosomes, 2) the absence of proteins in mTau exosomes, uniquely present in control exosomes, and 3) shared proteins which were significantly upregulated or downregulated in mTau compared with control exosomes. Notably, mTau exosomes (not control exosomes) contain ANP32A (also known as I1PP2A), an endogenous inhibitor of the PP2A phosphatase which regulates the phosphorylation state of p-Tau. Several of the mTau exosome-specific proteins have been shown to participate in AD mechanisms involving lysosomes, inflammation, secretases, and related processes. Furthermore, the mTau exosomes lacked a substantial portion of proteins present in control exosomes involved in pathways of localization, vesicle transport, and protein binding functions. The shared proteins present in both mTau and control exosomes represented exosome functions of vesicle-mediated transport, exocytosis, and secretion processes. These data illustrate mTau as a dynamic regulator of the biogenesis of exosomes to result in acquisition, deletion, and up- or downregulation of protein cargo to result in pathogenic mTau exosomes capable of in vivo propagation of p-Tau neuropathology in mouse brain.
Phosphorylation of α-synuclein at the Serine-129 site (α-syn Ser129P) is an established pathologic hallmark of synucleinopathies, and also a therapeutic target. In physiologic states, only a small fraction of total α-syn is phosphorylated at this site, and consequently, almost all studies to date have focused on putative pathologic roles of this post-translational modification. We noticed that unlike native (total) α-syn that is widely expressed throughout the brain, the overall pattern of α-syn Ser129P is restricted, suggesting intrinsic regulation and putative physiologic roles. Surprisingly, preventing phosphorylation at the Ser-129 site blocked the ability of α-syn to attenuate activity-dependent synaptic vesicle (SV) recycling; widely thought to reflect its normal function. Exploring mechanisms, we found that neuronal activity augments α-syn Ser-129P, and this phosphorylation is required for α-syn binding to VAMP2 and synapsin - two functional binding-partners that are necessary for α-syn function. AlphaFold2-driven modeling suggests a scenario where Ser129P induces conformational changes in the C-terminus that stabilizes this region and facilitates protein-protein interactions. Our experiments indicate that the pathology-associated Ser129P is an unexpected physiologic trigger of α-syn function, which has broad implications for pathophysiology and drug-development.
The accumulation
and propagation of hyperphosphorylated tau (p-Tau)
is a neuropathological hallmark occurring with neurodegeneration of
Alzheimer’s disease (AD). Extracellular vesicles, exosomes,
have been shown to initiate tau propagation in the brain. Notably,
exosomes from human-induced pluripotent stem cell (iPSC) neurons expressing
the AD familial A246E mutant form of presenilin 1 (mPS1) are capable
of inducing tau deposits in the mouse brain after in vivo injection. To gain insights into the exosome proteome cargo that
participates in propagating tau pathology, this study conducted proteomic
analysis of exosomes produced by human iPSC neurons expressing A246E
mPS1. Significantly, mPS1 altered the profile of exosome cargo proteins
to result in (1) proteins present only in mPS1 exosomes and not in
controls, (2) the absence of proteins in the mPS1 exosomes which were
present only in controls, and (3) shared proteins which were upregulated
or downregulated in the mPS1 exosomes compared to controls. These
results show that mPS1 dysregulates the proteome cargo of exosomes
to result in the acquisition of proteins involved in the extracellular
matrix and protease functions, deletion of proteins involved in RNA
and protein translation systems along with proteasome and related
functions, combined with the upregulation and downregulation of shared
proteins, including the upregulation of amyloid precursor protein.
Notably, mPS1 neuron-derived exosomes displayed altered profiles of
protein phosphatases and kinases involved in regulating the status
of p-tau. The dysregulation of exosome cargo proteins by mPS1 may
be associated with the ability of mPS1 neuron-derived exosomes to
propagate tau pathology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.